Skip to main content

With the current global shortage of lisdexamfetamine (VYVANSE) in mind, AADPA lodged a submission to the US Drug Enforcement Agency (DEA) in response to their call for feedback regarding their restriction of production quotas for certain controlled substances.

Submissions to the US DEA were also received from the RANZCP and the ADHD Foundation to further emphasise the growing concern in Australia. AADPA President, Prof. Dave Coghill’s also joined Sky News Australia presenter Jaynie Seal to discuss the issue. Watch the interview here.